Immunic Shares Phase 2 CALLIPER Trial Findings at CMSC Meeting 2026

Immunic, Inc., a biotechnology firm focused on developing oral therapies for neurological diseases, presented new data on its lead compound, vidofludimus calcium, at the CMSC Annual Meeting 2026. This trial data from the Phase 2 CALLIPER study underscores the potential of vidofludimus calcium in managing progressive multiple sclerosis (PMS).

One key highlight was a novel statistical method for assessing disability changes, which may offer a more comprehensive understanding of disease progression and potential neuroprotective effects. Findings demonstrate favorable outcomes for vidofludimus calcium in both safety and tolerability compared to placebo.

The patient-reported outcomes also indicated no adverse mood changes and suggested higher treatment satisfaction. These insights reinforce the compound's promising profile as Immunic continues its clinical development for PMS.